CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• OP. Inc. Y/Y Annual
Fibrogen Inc   (NASDAQ: FGEN)
Other Ticker:  
 
 

FGEN's Operating Income Growth by Quarter and Year

Fibrogen Inc 's Operating Income results by quarter and year

 



FGEN Operating Income (in millions $) FY 2025 FY 2024 FY 2023 FY 2022
4th Quarter December - -91.66 -54.19 -66.15
3rd Quarter September - -16.78 -63.48 -93.66
2nd Quarter June - -10.92 -88.05 -78.22
1st Quarter March -14.92 -31.06 -76.09 -62.99
FY   -14.92 -150.42 -281.81 -301.02

FGENs Annual Operating Income
Fibrogen Inc 's Operating Income in the fiscal year 2024 $ -150.42 millions
Fibrogen Inc 's Operating Income in the fiscal year 2023 $ -281.82 millions
Fibrogen Inc 's Operating Income in the fiscal year 2022 $ -301.03 millions
Fibrogen Inc 's Operating Income in the fiscal year 2021 $ -288.53 millions
Fibrogen Inc 's Operating Income in the fiscal year 2019 $ -89.31 millions




FGEN Operating Income first quarter 2025 Y/Y Growth Comment
Fibrogen Inc in the first quarter 2025 recorded Operating Loss of $ -14.92 millions.

According to the results reported in the first quarter 2025, Fibrogen Inc achieved the best Operating Income growth in Major Pharmaceutical Preparations industry. While Fibrogen Inc ' s Operating Income no change of 0% ranks overall at the positon no. in the first quarter 2025.

Explain Operating Income growth


FGEN Operating Income ( Y/Y Growth %) 2025
 2024 2023 2022
4th Quarter December - - - -
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March - - - -
FY   - - - -

Financial Statements
Fibrogen Inc 's first quarter 2025 Operating Income $ -14.92 millions FGEN's Income Statement
Fibrogen Inc 's first quarter 2024 Operating Income $ -31.06 millions Quarterly FGEN's Income Statement


FGEN Operating Income (Quarter on Quarter Growth %)

 2025
 2024 2023 2022
4th Quarter December - - - -
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March - - - -
FY (Year on Year)   - - - -


Compare FGEN Profitability >> Back to FGEN Growth rate Comparisons >>


Operating Income first quarter 2025 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Operating Income Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Operating Income first quarter 2025 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Operating Income Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Operating Income by Quarter for the Fiscal Years 2022, 2023, 2024, 2025

Fibrogen Inc 's Q/Q Operating Income Growth


Operating Income Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


FGEN's I. Quarter Q/Q Operating Income Comment
Despite the fact, that Fibrogen Inc in the I. Quarter 2025 revealed Operating Loss of $ -14.92 millions, it should be mentioned, that those numbers are recovery in contrast to the -91.66 millions in the fourth quarter.

Within Major Pharmaceutical Preparations industry Fibrogen Inc achieved highest sequential Operating Income growth. While Fibrogen Inc 's Operating Income growth quarter on quarter, overall rank is .


Operating Income Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Operating Income Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Operating Income Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


FGEN's I. Quarter Q/Q Operating Income Comment
Despite the fact, that Fibrogen Inc in the I. Quarter 2025 revealed Operating Loss of $ -14.92 millions, it should be mentioned, that those numbers are recovery in contrast to the -91.66 millions in the fourth quarter.

Within Major Pharmaceutical Preparations industry Fibrogen Inc achieved highest sequential Operating Income growth. While Fibrogen Inc 's Operating Income growth quarter on quarter, overall rank is .


Fibrogen Inc 's 12 Months Operating Income Growth Year on Year


Operating Income TTM Growth

12 Months Ending
(Mar 31 2025)		 12 Months Ending
(Dec 31 2024)		 12 Months Ending
(Sep 30 2024)		 12 Months Ending
(Jun 30 2024)		 12 Months Ending
(Mar 31 2024)
Cumulative Operating Income 12 Months Ending $ -134.27 $ -150.42 $ -112.95 $ -159.66 $ -236.79
Y / Y Operating Income Growth (TTM) - - - - -
Year on Year Operating Income Growth Overall Ranking # # # # #
Seqeuential Operating Income Change (TTM) - - - - -
Seq. Operating Income Growth (TTM) Overall Ranking # # # # #


Cumulative Operating Income growth Comment


Fibrogen Inc achieved highest trailing twelve month year on year Operating Income growth. While overall Operating Income growth ranking, remained unchanged compare to the previous quarter at no. .

Operating Income TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Operating Income TTM Y/Y Growth Statistics
High Average Low
0 %
 0 %
0 %
 


Operating Income TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Operating Income growth Comment


Fibrogen Inc achieved highest trailing twelve month year on year Operating Income growth. While overall Operating Income growth ranking, remained unchanged compare to the previous quarter at no. .


Operating Income TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Operating Income TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Operating Income TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Operating Income Growth
Major Pharmaceutical Preparations Industry Operating Income Growth Trends and Statistics
Healthcare Sector Operating Income Growth Statistics
Operating Income Growth Trends for overall market
FGEN's Operating Income Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Operating Income Growth
Lowest Ranking Operating Income Growth
Operating Income Growth for FGEN's Competitors
Operating Income Growth for Fibrogen Inc 's Suppliers
Operating Income Growth for FGEN's Customers

You may also want to know
FGEN's Annual Growth Rates FGEN's Profitability Ratios FGEN's Asset Turnover Ratio FGEN's Dividend Growth
FGEN's Roe FGEN's Valuation Ratios FGEN's Financial Strength Ratios FGEN's Dividend Payout Ratio
FGEN's Roa FGEN's Inventory Turnover Ratio FGEN's Growth Rates FGEN's Dividend Comparisons



Companies with similar Operating Income no change for the quarter ending Mar 31 2025 within Healthcare SectorY/Y Change %Operating Income for the quarter ending Mar 31 2025
Bausch Health Companies Inc -1.78%$ -1.779 millions
National Research Corporation-1.87%$ -1.872 millions
Iqvia Holdings Inc -1.98%$ -1.976 millions
Fonar Corporation-2.24%$ -2.242 millions
Msa Safety Inc-2.93%$ -2.935 millions
Lantheus Holdings Inc -4.28%$ -4.284 millions
Mettler Toledo International Inc-6.21%$ -6.214 millions
Bioventus Inc -8.60%$ -8.598 millions
Pfizer Inc-8.65%$ -8.654 millions
Davita Inc -9.28%$ -9.281 millions
Steris Plc-11.86%$ -11.855 millions
West Pharmaceutical Services Inc -12.87%$ -12.866 millions
Stryker Corp-13.89%$ -13.889 millions
Align Technology inc -14.94%$ -14.945 millions
Oak Woods Acquisition Corp-15.07%$ -15.073 millions
3m Company-16.99%$ -16.989 millions
Elanco Animal Health Incorporated-17.24%$ -17.241 millions
Carlisle Companies Incorporated-18.47%$ -18.472 millions
Surgery Partners Inc -18.55%$ -18.553 millions
Utah Medical Products Inc-18.80%$ -18.800 millions
Envista Holdings Corporation-18.92%$ -18.919 millions
Regeneron Pharmaceuticals Inc -21.25%$ -21.254 millions
Amphastar Pharmaceuticals Inc -22.32%$ -22.322 millions
Acadia Healthcare Company Inc -25.50%$ -25.495 millions
Becton Dickinson And Company-25.61%$ -25.613 millions
Essa Pharma inc -29.65%$ -29.655 millions
Biogen Inc -30.31%$ -30.313 millions
Mimedx Group Inc -37.48%$ -37.483 millions
Organon and Co -38.03%$ -38.032 millions
Charles River Laboratories International inc -40.73%$ -40.728 millions


Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com